Let’s Reach Your Development Milestones Together
Dr. Marcus Mreyen, PhD
Director, Business Development, Central Europe
Marcus Mreyen holds a PhD in chemistry and spent two years in the protein analytical field at Macquarie University and the Australian Proteome Analysis Facility (APAF). Starting at Protagen AG in 2000, he successfully worked as a Project Manager and supported multiple customer projects in the various fields of protein characterization. He transferred and deepened his technical understanding while working for Shimadzu Europe, as a Product Manager for Mass Spectrometry and Life Science products. During this time, he assisted customers in pharma and biotech in Europe and Russia, before returning in 2013 to ProtaGene as a Head for Business Development.
Since then, he has supported a large variety of international companies in their Biosimilar or NBE developments from early phases of development to Phase 3, as well as for GMP release and stability testing.
Analytical Solutions from Research to Market
Biologic Therapeutics
Platform Expertise
-
mAbs
-
Bispecifics/Multispecifics
-
Recombinant Proteins—Including Complex, Highly Glycosylated Proteins
-
Multi-subunit Complexes—Protein, Nucleotide, Ligand
-
Fusion Proteins
-
Enzyme Replacement Therapies
-
ADCs and Protein Conjugates
-
PEGylated Proteins
-
Biosimilars
-
Vaccines, Including Subunit/Recombinant
Cell and Gene Therapeutic Platform Expertise
-
Capsid-based Vectors
-
bullet Created with Sketch. Complex, Envelope Vectors
-
bullet Created with Sketch. Non-viral Vectors
-
bullet Created with Sketch. Genetic Engineering